{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:11:48Z","timestamp":1788405108080,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA275766"],"award-info":[{"award-number":["R01CA275766"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007408","name":"Medical Center, University of Pittsburgh","doi-asserted-by":"publisher","award":["SCR_025361"],"award-info":[{"award-number":["SCR_025361"]}],"id":[{"id":"10.13039\/100007408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007408","name":"Medical Center, University of Pittsburgh","doi-asserted-by":"publisher","award":["SCR_025360"],"award-info":[{"award-number":["SCR_025360"]}],"id":[{"id":"10.13039\/100007408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030715","name":"UPMC Hillman Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030715","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["ZIA BC 011800"],"award-info":[{"award-number":["ZIA BC 011800"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["ZIA BC 012066"],"award-info":[{"award-number":["ZIA BC 012066"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016610","name":"Andrew McDonough B Positive Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017286","name":"US Department of Energy Office of Isotope R and D and Production","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017286","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.05.030","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:41:57Z","timestamp":1780443717000},"page":"5207-5221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Ira","family":"Phadke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Nambiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Yong","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hima","family":"Makala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woonghee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwamena E.","family":"Baidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanza","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reona","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Schmiechen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Maiarana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jangsuk","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sheehan-Klenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Edinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangfeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falguni","family":"Basuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Swenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie N.","family":"Nedrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8328-746X","authenticated-orcid":false,"given":"Ravi B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy E.","family":"Escorcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5143-2055","authenticated-orcid":false,"given":"Rosa","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.05.030_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccell.2017.08.003","article-title":"Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma","volume":"32","author":"Bosse","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2026.05.030_bib2","first-page":"E6623","article-title":"Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma","volume":"114","author":"Li","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.05.030_bib3","series-title":"SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics","author":"Ries LAG","year":"2007"},{"key":"10.1016\/j.ymthe.2026.05.030_bib4","article-title":"CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice","volume":"2","author":"Li","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.05.030_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.030_bib6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.030_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","article-title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","volume":"40","author":"Heitzeneder","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2026.05.030_bib8","doi-asserted-by":"crossref","first-page":"e005881","DOI":"10.1136\/jitc-2022-005881","article-title":"Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma","volume":"11","author":"Sun","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.030_bib9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/pbc.21932","article-title":"(123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial","volume":"52","author":"Vik","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ymthe.2026.05.030_bib10","first-page":"1753","article-title":"Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors","volume":"35","author":"Gelfand","year":"1994","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.05.030_bib11","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2026.05.030_bib12","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic Performance of (18)F-DCFPyL-PET\/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.05.030_bib13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1053\/j.semnuclmed.2024.10.003","article-title":"Highlighting New Research Trends on Zirconium-89 Radiopharmaceuticals Beyond Antibodies","volume":"54","author":"Duvenhage","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.05.030_bib14","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s11307-016-0951-z","article-title":"[(89)Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer","volume":"18","author":"Laforest","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.ymthe.2026.05.030_bib15","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.2967\/jnumed.115.172031","article-title":"Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET\/CT","volume":"57","author":"Ulaner","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.05.030_bib16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.2967\/jnumed.112.117218","article-title":"89Zr-bevacizumab PET imaging in primary breast cancer","volume":"54","author":"Gaykema","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.05.030_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2967\/jnumed.114.144840","article-title":"89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment","volume":"56","author":"Oosting","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.05.030_bib18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.115.167643","article-title":"89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease","volume":"57","author":"Oosting","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.05.030_bib19","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.18632\/oncotarget.13910","article-title":"Quantitative assessment of Zirconium-89 labeled cetuximab using PET\/CT imaging in patients with advanced head and neck cancer: a theragnostic approach","volume":"8","author":"Even","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2026.05.030_bib20","doi-asserted-by":"crossref","first-page":"30384","DOI":"10.18632\/oncotarget.4672","article-title":"89Zr-cetuximab PET imaging in patients with advanced colorectal cancer","volume":"6","author":"Menke-van der Houven van Oordt","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2026.05.030_bib21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13075-016-1166-z","article-title":"B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients","volume":"18","author":"Bruijnen","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ymthe.2026.05.030_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169828","article-title":"Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed\/Refractory Diffuse Large B Cell Lymphoma","volume":"12","author":"Jauw","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.05.030_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29117","article-title":"A safety and feasibility trial of (131) I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study","volume":"68","author":"Weiss","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ymthe.2026.05.030_bib24","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2005.03.6400","article-title":"Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study","volume":"24","author":"Matthay","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.030_bib25","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.21.00703","article-title":"Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium","volume":"39","author":"DuBois","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.030_bib26","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.addr.2008.04.009","article-title":"Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications","volume":"60","author":"Miederer","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.05.030_bib27","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group","volume":"38","author":"Mody","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.030_bib28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbmt.2014.12.008","article-title":"131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study","volume":"21","author":"Yanik","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2026.05.030_bib29","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.030_bib30","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.030_bib31","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.05.030_bib32","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2967\/jnumed.119.239558","article-title":"The Role of (89)Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals","volume":"62","author":"van Dongen","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.05.030_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/jlcr.3605","article-title":"(89) Zr-ImmunoPET companion diagnostics and their impact in clinical drug development","volume":"61","author":"McKnight","year":"2018","journal-title":"J. Labelled Comp. Radiopharm."},{"key":"10.1016\/j.ymthe.2026.05.030_bib34","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.05.030_bib35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma","volume":"78","author":"Weiss","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.05.030_bib36","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2021.0168","article-title":"Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review","volume":"7","author":"Hauth","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2026.05.030_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/cancers16010191","article-title":"Comparative Study of the Effect of Radiation Delivered by Lutetium-177 or Actinium-225 on Anti-GD2 Chimeric Antigen Receptor T Cell Viability and Functions","volume":"16","author":"Sodji","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2026.05.030_bib38","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1038\/s41467-019-11906-2","article-title":"Tumor-reprogrammed resident T cells resist radiation to control tumors","volume":"10","author":"Arina","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.05.030_bib39","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.220157","article-title":"A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements","volume":"5","author":"Burkett","year":"2023","journal-title":"Radiol. Imaging Cancer"},{"key":"10.1016\/j.ymthe.2026.05.030_bib40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijrobp.2022.08.010","article-title":"A Primer on Radiopharmaceutical Therapy","volume":"115","author":"Salerno","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ymthe.2026.05.030_bib41","doi-asserted-by":"crossref","first-page":"e001875","DOI":"10.1136\/jitc-2020-001875","article-title":"Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.030_bib42","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2026.05.030_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.05.030_bib44","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.ijrobp.2022.10.028","article-title":"Radiation-Induced Remodeling of the Tumor Microenvironment Through Tumor Cell-Intrinsic Expression of cGAS-STING in Esophageal Squamous Cell Carcinoma","volume":"115","author":"Nakajima","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ymthe.2026.05.030_bib45","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","article-title":"Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation","volume":"112","author":"Du","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ymthe.2026.05.030_bib46","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.ymthe.2026.05.030_bib47","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1073\/pnas.88.4.1394","article-title":"scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair","volume":"88","author":"Biedermann","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.05.030_bib48","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/2326-6066.CIR-24-0975","article-title":"GPC2-Targeted CAR T Cells Engineered with NFAT-Inducible Membrane-Tethered IL15\/IL21 Exhibit Enhanced Activity against Neuroblastoma","volume":"13","author":"Okada","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.05.030_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100942","article-title":"Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse models","volume":"2","author":"Li","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.ymthe.2026.05.030_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/1536012119829986","article-title":"Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody","volume":"18","author":"Jagoda","year":"2019","journal-title":"Mol. Imaging"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:18:33Z","timestamp":1788362313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626004740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525001626004740"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.030","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}